Tong 1997 (CIFN 3µg).

Methods	Allocation concealment: unclear. Blinding: yes. Intention to treat: yes. Methodological score: 21.
Participants	NAIVE PATIENTS WITH CHRONIC HEPATITIS C Arms: 232/240 Excluded: NDA Mean age: 43/43 % males: 72/72 % transfusion: 27/22 % drug abuse: 40/44 % cirrhosis: 39/24 Genotypes: NDA Disease duration: NDA
Interventions	Experimental 1: C‐IFN 3 µg TIW x 6 mo Experimental 2: Alfa‐2b IFN 15 µg TIW x 6 mo Follow‐up: 6 mo
Outcomes	‐ biochemical ETR and SR ‐ virologic ETR and SR
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear